Vivani Medical, Inc. is a biotechnology company focused on developing innovative drug delivery solutions to improve patient outcomes in chronic disease management
The company's primary expertise lies in the creation of miniaturized implantable devices that provide sustained release of therapeutic agents over extended periods. By enhancing the delivery of medications for conditions such as diabetes and obesity, Vivani aims to offer safer, more effective alternatives to traditional treatment methods, thereby transforming the way patients manage their health. The commitment to advancing medical technology drives Vivani's research and development endeavors, with a vision to make a meaningful impact on healthcare.
Vivani Medical launches first-in-human trial of its exenatide implant in Australia, aiming to support chronic weight management with innovative GLP-1 technology.
Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial will assess safety, tolerability, and weight loss outcomes, with data expected by 2025.
Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial is set to begin in Q4 2024.
Vivani Medical plans to start the first clinical study of the NPM-115 program in Australia in Q4 2024. The study will evaluate a 6-month GLP-1 implant for chronic weight management in obese or overweight patients. The trial includes comparisons with semaglutide and exenatide injections.
Vivani Medical shares are trading higher Thursday after the company announced the FDA cleared the Investigational New Drug application and lifted the clinical hold on NPM-119.
Vivani Medical cleared FDA for NPM-119 trial in type 2 diabetes. LIBERATE-1 will assess safety, tolerability, & pharmacokinetics. NPM-115 & NPM-139 also in development for weight management.
Vivani Medical announced proof-of-concept data for a subdermal exenatide implant designed for feline obesity and diabetes, which was published in BMC Veterinary Research.
Shares of Bitdeer Technologies Group (NASDAQBTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.27% to 38,867.91 while the NASDAQ fell 0.50% to 15,954.75. The S&P 500 also fell, dropping, 0.18% to 5,068.92.
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 50 points on Wednesday. The Dow traded down 0.19% to 38,899.92 while the NASDAQ fell 0.31% to 15,985.25. The S&P 500 also fell, dropping, 0.11% to 5,072.67.
U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.52% to 38,770.83 while the NASDAQ fell 0.63% to 15,933.71. The S&P 500 also fell, dropping, 0.33% to 5,061.21.
